LIVER DISEASES

Gerd KULLAK-UBLICK

SITE

Liver Int. 2022;In press. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Björnsson ES, Stephens C, Atallah E, Robles-Diaz M, Alvarez-Alvarez I, Gerbes A, Weber S, Stirnimann G, Kullak-Ublick G, Cortez-Pinto H, Grove JI, Lucena MI, Andrade RJ, Aithal GP. PubMed

Front Med (Lausanne). 2022;8:800421.The Role of NF-kB in the downregulation of Organic Cation Transporter 2 expression and renal cation secretion in kidney disease. Han C, Zheng J, Wang F, Lu Q, Chen Q, Hu A, Visentin M, Kullak-Ublick GA, Gai Z, Chu L. PubMed

Expert Opin Drug Metab Toxicol. 2021;17:1327-1343. Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. Expert Opin. Atallah E, Freixo C, Alvarez-Alvarez I, Cubero FJ, Gerbes AL, Kullak-Ublick GA, Aithal GP. PubMed

Int J Mol Sci. 2020;21:7890. Organic Cation Transporters in human physiology, pharmacology, and toxicology. Samodelov SL, Kullak-Ublick GA, Gai Z, Visentin M. PubMed

J Pharmacol Exp Ther. 2020:375:239-246. Untargeted metabolomics reveals anaerobic glycolysis as a novel target of the hepatotoxic antidepressant nefazodone. Krajnc E, Visentin M, Gai Z, Stieger B, Samodelov SL, Häusler S, Kullak-Ublick GA. PubMed

Mol Pharmacol. 2020;97:314-323. Obeticholic acid ameliorates Valproic Acid-induced hepatic steatosis and oxidative stress. Gai Z, Krajnc E, Samodelov SL, Visentin M, Kullak-Ublick GA. PubMed

J Pharmacol Exp Ther. 2020;372:46-53. Plasma membrane cholesterol regulates the allosteric binding of 1-Methyl-4-Phenylpyridinium to Organic Cation Transporter 2 (SLC22A2). Hörmann S, Gai Z, Kullak-Ublick GA, Visentin M. PubMed

Nat Rev Dis Primers. 2019;5:58. Drug-induced liver injury. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. PubMed

Pharmacol Res. 2020;154:104234. Drugs and hepatic transporters: A review. Jetter A, Kullak-Ublick GA. PubMed

Nat Rev Dis Primers. 2019;5:58. Drug-induced liver injury. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. PubMed

Liver Int. 2019;39:2350-2359. microRNA-206 modulates the hepatic expression of the organic anion-transporting polypeptide 1B1. El Saadany T, van Rosmalen B, Gai Z, Hiller C, Verheij J, Stieger B, van Gulik T, Visentin M, Kullak-Ublick GA. PubMed

Pharmacol Res. 2020;154:104234. Drugs and hepatic transporters: A review. Jetter A, Kullak-Ublick GA. PubMed

J Hepatol. 2019;70:1222-1261. EASL clinical practice guidelines: Drug-induced liver injury. Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH. PubMed

Gastroenterology. 2019;156:1707-1716.e2. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, Long N, Molokhia M, Nelson MR, Odin JA, Pirmohamed M, Rafnar T, Serrano J, Stefánsson K, Stolz A, Daly AK, Aithal GP, Watkins PB; Drug-Induced Liver Injury Network (DILIN) investigators; International DILI consortium (iDILIC). PubMed

Eur J Clin Pharmacol. 2019;75:409-416. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Essers D, Schäublin M, Kullak-Ublick GA, Weiler S. PubMed

Drug Discov Today. 2019;24:285-292. Safety differentiation: emerging competitive edge in drug development. Uteng M, Urban L, Brees D, Muller PY, Kullak-Ublick GA, Bouchard P, Tougas G, Chibout SD. PubMed

Drug Metab Dispos. 2018;46:1129-1136. Fluorocholine transport mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for imaging of kidney tumors. Visentin M, Torozi A, Gai Z, Häusler S, Li C, Hiller C, Schraml PH, Moch H, Kullak-Ublick GA. PubMed

Toxicol Sci. 2018;163:265-278. Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation. Schadt HS, Wolf A, Mahl JA, Wuersch K, Couttet P, Schwald M, Fischer A, Lienard M, Emotte C, Teng CH, Skuba E, Richardson TA, Manenti L, Weiss A, Graus Porta D, Fairhurst RA, Kullak-Ublick GA, Chibout SD, Pognan F, Kluwe W, Kinyamu-Akunda J. PubMed

Hepatology. 2018; in press. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, Kirby P, Marcinak J, Ormarsdottir S, Schomaker SJ, Schuppe-Koistinen I, Wolenski F, Arber N, Merz M, Sauer JM, Andrade RJ, van Bömmel F, Poynard T, Watkins PB. PubMed

PLoS One. 2017;12:e0189436. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, Thabut D, Rudler M, Thibault V, Schuppe-Koistinen I, Bonnefont-Rousselot D, Hainque B, Imbert-Bismut F, Merz M7,, Kullak-Ublick G, Andrade R, van Boemmel F, Schott E, Poynard T; Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière; Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium. PubMed

Drug Metab Dispos. 2017;45:1240-1244. Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Visentin M, Gai Z, Torozi A, Hiller C, Kullak-Ublick GA. PubMed

Biochim Biophys Acta. 2017; S0925-4439(17)30315-0.  Drug-induced bile duct injury. Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. PubMed

Gut. 2017;66:1154-1164. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. PubMed

Gastroenterology. 2017;152:1078-1089. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a Genome-Wide Association Study. Nicoletti P and International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. PubMed

Drug Metab Dispos. 2017;45:166-173. Impact of Organic Cation Transporters (OCT-SLC22A) on differential diagnosis of intrahepatic lesions. Liver imaging. Visentin M, van Rosmalen BV, Hiller C, Bieze M, Hofstetter L, Verheij J, Kullak-Ublick GA, Koepsell H, Phoa SS, Tamai I, Bennink RJ, van Gulik TM, Stieger B. PubMed

Life Sci. 2016;156:47-56. Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Krattinger R, Boström A, Lee SM, Thasler WE, Schiöth HB, Kullak-Ublick GA, Mwinyi J. PubMed

Am J Physiol Gastrointest Liver Physiol. 2016;310:G1044-51. microRNA-192 suppresses the expression of the farnesoid X receptor. Krattinger R, Boström A, Schiöth HB, Thasler WE, Mwinyi J, Kullak-Ublick GA. PubMed

Clin Res Hepatol Gastroenterol. 2016;40:257-66. Bile acids in drug induced liver injury: Key players and surrogate markers. Schadt HS, Wolf A, Pognan F, Chibout SD, Merz M, Kullak-Ublick GA. PubMed

J Biol Chem. 2016;291:2397-411. Farnesoid X receptor protects against kidney Injury in uninephrectomized obese mice. Gai Z, Gui T, Hiller C, Kullak-Ublick GA. PubMed

J Pharmacol Exp Ther. 2015;355:145-51. Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2. Visentin M, Stieger B, Merz M, Kullak-Ublick GA. PubMed

F1000 Prime Rep. 2015;7:34. Drug-induced liver injury: the dawn of biomarkers? Weiler S, Merz M, Kullak-Ublick GA. PubMed

Liver Int. 2015;35:1152-61. The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes. Schaffner CA, Mwinyi J, Gai Z, Thasler WE, Eloranta JJ, Kullak-Ublick GA. PubMed

Am J Physiol Renal Physiol. 2014;306:F130-7. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Gai Z, Chu L, Hiller C, Arsenijevic D, Penno CA, Montani JP, Odermatt A, Kullak-Ublick GA. PubMed

Transl Res. 2012;160:298-308. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Trdan Lušin T, Mrhar A, Stieger B, Kullak-Ublick GA, Marc J, Ostanek B, Zavratnik A, Kristl A, Berginc K, Delić K, Trontelj J. PubMed

Am J Physiol Gastrointest Liver Physiol. 2012;302:G123-33. Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. Ma L, Jüttner M, Kullak-Ublick GA, Eloranta JJ. PubMed

J Hepatol. 2011;54:738-45. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. de Graaf W1, Häusler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. PubMed

Mol Pharmacol. 2010;78:1079-87. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1α (HNF-1α). Klein K, Jüngst C, Mwinyi J, Stieger B, Krempler F, Patsch W, Eloranta JJ, Kullak-Ublick GA. PubMed

Hepatology. 2010;52:748-61. Pharmacogenetics of drug-induced liver injury. Russmann S, Jetter A, Kullak-Ublick GA. PubMed

Curr Med Chem. 2009;16:3041-53. Current concepts of mechanisms in drug-induced hepatotoxicity. Russmann S1, Kullak-Ublick GA, Grattagliano I. PubMed

Pharmacogenomics. 2008;9:597-624. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Zaïr ZM1, Eloranta JJ, Stieger B, Kullak-Ublick GA. PubMed

Pharmacogenet Genomics. 2007;17:47-60. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed

Pharmacogenet Genomics. 2007;17:47-60.Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed

Drug Metab Dispos. 2006;34:1582-99. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, Stieger B, Kullak-Ublick GA, Kerb R. PubMed

Mol Pharmacol. 2006;70:627-36. Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression. Qadri I, Iwahashi M, Kullak-Ublick GA, Simon FR. PubMed

J Pharmacol Exp Ther. 2006;317:778-85. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. Saborowski M1, Kullak-Ublick GA, Eloranta JJ. PubMed

Methods Enzymol. 2005;400:511-30.Coordinate transcriptional regulation of transport and metabolism. Eloranta JJ1, Meier PJ, Kullak-Ublick GA. PubMed

Am J Physiol Gastrointest Liver Physiol. 2006;290:G476-85. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Landrier JF1, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. PubMed

Mol Endocrinol. 2006;20:65-79. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Eloranta JJ, Jung D, Kullak-Ublick GA. PubMed